Lyndsay Harris, MD
A trickle of positive findings from NCI-MATCH, a precision medicine trial of numerous agents across tumor types, has encouraged investigators to broaden the number of trial arms, which now stand at 40, and expand enrollment. Since the trial’s inception in 2015, molecular testing has been conducted on the tumors of 6000 patients and many arms have already closed to enrollment. Investigators expect to report more findings soon.
... to read the full story